Literature DB >> 25866966

Ube3a reinstatement identifies distinct developmental windows in a murine Angelman syndrome model.

Sara Silva-Santos, Geeske M van Woerden, Caroline F Bruinsma, Edwin Mientjes, Mehrnoush Aghadavoud Jolfaei, Ben Distel, Steven A Kushner, Ype Elgersma.   

Abstract

Angelman syndrome (AS) is a severe neurodevelopmental disorder that results from loss of function of the maternal ubiquitin protein ligase E3A (UBE3A) allele. Due to neuron-specific imprinting, the paternal UBE3A copy is silenced. Previous studies in murine models have demonstrated that strategies to activate the paternal Ube3a allele are feasible; however, a recent study showed that pharmacological Ube3a gene reactivation in adulthood failed to rescue the majority of neurocognitive phenotypes in a murine AS model. Here, we performed a systematic study to investigate the possibility that neurocognitive rescue can be achieved by reinstating Ube3a during earlier neurodevelopmental windows. We developed an AS model that allows for temporally controlled Cre-dependent induction of the maternal Ube3a allele and determined that there are distinct neurodevelopmental windows during which Ube3a restoration can rescue AS-relevant phenotypes. Motor deficits were rescued by Ube3a reinstatement in adolescent mice, whereas anxiety, repetitive behavior, and epilepsy were only rescued when Ube3a was reinstated during early development. In contrast, hippocampal synaptic plasticity could be restored at any age. Together, these findings suggest that Ube3a reinstatement early in development may be necessary to prevent or rescue most AS-associated phenotypes and should be considered in future clinical trial design.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25866966      PMCID: PMC4463212          DOI: 10.1172/JCI80554

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  25 in total

1.  Rescue of neurological deficits in a mouse model for Angelman syndrome by reduction of alphaCaMKII inhibitory phosphorylation.

Authors:  Geeske M van Woerden; Karen D Harris; Mohammad Reza Hojjati; Richard M Gustin; Shenfeng Qiu; Rogerio de Avila Freire; Yong-hui Jiang; Ype Elgersma; Edwin J Weeber
Journal:  Nat Neurosci       Date:  2007-01-28       Impact factor: 24.884

Review 2.  Neurological aspects of the Angelman syndrome.

Authors:  Charles A Williams
Journal:  Brain Dev       Date:  2005-03       Impact factor: 1.961

3.  Fragile X syndrome therapeutics S(C)TEP through the developmental window.

Authors:  Aditi Bhattacharya; Eric Klann
Journal:  Neuron       Date:  2012-04-12       Impact factor: 17.173

4.  Angelman syndrome: Drugs to awaken a paternal gene.

Authors:  Arthur L Beaudet
Journal:  Nature       Date:  2011-12-21       Impact factor: 49.962

Review 5.  Angelman syndrome: insights into genomic imprinting and neurodevelopmental phenotypes.

Authors:  Angela M Mabb; Matthew C Judson; Mark J Zylka; Benjamin D Philpot
Journal:  Trends Neurosci       Date:  2011-05-17       Impact factor: 13.837

6.  Reversal of neurological defects in a mouse model of Rett syndrome.

Authors:  Jacky Guy; Jian Gan; Jim Selfridge; Stuart Cobb; Adrian Bird
Journal:  Science       Date:  2007-02-08       Impact factor: 47.728

7.  Mutation of the Angelman ubiquitin ligase in mice causes increased cytoplasmic p53 and deficits of contextual learning and long-term potentiation.

Authors:  Y H Jiang; D Armstrong; U Albrecht; C M Atkins; J L Noebels; G Eichele; J D Sweatt; A L Beaudet
Journal:  Neuron       Date:  1998-10       Impact factor: 17.173

8.  Adeno-associated virus-mediated rescue of the cognitive defects in a mouse model for Angelman syndrome.

Authors:  Jennifer L Daily; Kevin Nash; Umesh Jinwal; Todd Golde; Justin Rogers; Melinda M Peters; Rebecca D Burdine; Chad Dickey; Jessica L Banko; Edwin J Weeber
Journal:  PLoS One       Date:  2011-12-09       Impact factor: 3.240

9.  Topoisomerase inhibitors unsilence the dormant allele of Ube3a in neurons.

Authors:  Hsien-Sung Huang; John A Allen; Angela M Mabb; Ian F King; Jayalakshmi Miriyala; Bonnie Taylor-Blake; Noah Sciaky; J Walter Dutton; Hyeong-Min Lee; Xin Chen; Jian Jin; Arlene S Bridges; Mark J Zylka; Bryan L Roth; Benjamin D Philpot
Journal:  Nature       Date:  2011-12-21       Impact factor: 49.962

10.  Behavioral phenotypes of Disc1 missense mutations in mice.

Authors:  Steven J Clapcote; Tatiana V Lipina; J Kirsty Millar; Shaun Mackie; Sheila Christie; Fumiaki Ogawa; Jason P Lerch; Keith Trimble; Masashi Uchiyama; Yoshiyuki Sakuraba; Hideki Kaneda; Toshihiko Shiroishi; Miles D Houslay; R Mark Henkelman; John G Sled; Yoichi Gondo; David J Porteous; John C Roder
Journal:  Neuron       Date:  2007-05-03       Impact factor: 17.173

View more
  88 in total

1.  Neurodevelopmental disease: A molecular tightrope.

Authors:  Ype Elgersma
Journal:  Nature       Date:  2015-10-01       Impact factor: 49.962

2.  Acute and crucial requirement for MeCP2 function upon transition from early to late adult stages of brain maturation.

Authors:  Fang Du; Minh Vu Chuong Nguyen; Ariel Karten; Christy A Felice; Gail Mandel; Nurit Ballas
Journal:  Hum Mol Genet       Date:  2016-02-16       Impact factor: 6.150

3.  UBE3A regulates the transcription of IRF, an antiviral immunity.

Authors:  Ryohei Furumai; Kota Tamada; Xiaoxi Liu; Toru Takumi
Journal:  Hum Mol Genet       Date:  2019-06-15       Impact factor: 6.150

4.  The Autism Protein Ube3A/E6AP Remodels Neuronal Dendritic Arborization via Caspase-Dependent Microtubule Destabilization.

Authors:  Natasha Khatri; James P Gilbert; Yuda Huo; Roozhin Sharaflari; Michael Nee; Hui Qiao; Heng-Ye Man
Journal:  J Neurosci       Date:  2017-12-04       Impact factor: 6.167

5.  Dissociation of locomotor and cerebellar deficits in a murine Angelman syndrome model.

Authors:  Caroline F Bruinsma; Martijn Schonewille; Zhenyu Gao; Eleonora M A Aronica; Matthew C Judson; Benjamin D Philpot; Freek E Hoebeek; Geeske M van Woerden; Chris I De Zeeuw; Ype Elgersma
Journal:  J Clin Invest       Date:  2015-10-20       Impact factor: 14.808

Review 6.  Epigenetic and Cellular Diversity in the Brain through Allele-Specific Effects.

Authors:  Wei-Chao Huang; Kathleen Bennett; Christopher Gregg
Journal:  Trends Neurosci       Date:  2018-08-08       Impact factor: 13.837

7.  CRISPR/Cas9 directed to the Ube3a antisense transcript improves Angelman syndrome phenotype in mice.

Authors:  Ralf S Schmid; Xuefeng Deng; Priyalakshmi Panikker; Msema Msackyi; Camilo Breton; James M Wilson
Journal:  J Clin Invest       Date:  2021-03-01       Impact factor: 14.808

Review 8.  Drug development for neurodevelopmental disorders: lessons learned from fragile X syndrome.

Authors:  Elizabeth M Berry-Kravis; Lothar Lindemann; Aia E Jønch; George Apostol; Mark F Bear; Randall L Carpenter; Jacqueline N Crawley; Aurore Curie; Vincent Des Portes; Farah Hossain; Fabrizio Gasparini; Baltazar Gomez-Mancilla; David Hessl; Eva Loth; Sebastian H Scharf; Paul P Wang; Florian Von Raison; Randi Hagerman; Will Spooren; Sébastien Jacquemont
Journal:  Nat Rev Drug Discov       Date:  2017-12-08       Impact factor: 84.694

9.  Ube3a reinstatement mitigates epileptogenesis in Angelman syndrome model mice.

Authors:  Bin Gu; Kelly E Carstens; Matthew C Judson; Katherine A Dalton; Marie Rougié; Ellen P Clark; Serena M Dudek; Benjamin D Philpot
Journal:  J Clin Invest       Date:  2018-11-19       Impact factor: 14.808

Review 10.  Monogenic mouse models of autism spectrum disorders: Common mechanisms and missing links.

Authors:  S W Hulbert; Y-H Jiang
Journal:  Neuroscience       Date:  2015-12-28       Impact factor: 3.590

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.